No abstract available.
Tetanus*

No abstract available.
Tetanus*

No abstract available.
Tetanus*

The Institute of Vaccine and Biologicals has recently released on market a purified tetanus antitoxin. The average potency of the product reached  3.000 IU/ml. The N-protein content is  70mg/ml
Tetanus Antitoxin ; Diseases ; Tetanus

An investigation on 454 mothers with children under 1 year showed that the rate of children who had been protected from tetanus before dilivery was 88.1%. The causes of the rest pregnant women had not vaccineated was the difficulties and insufficient information. The distribution and keep of the vaccineation cards was not good. Survey data and reports was not different.
Tetanus ; Child

79 serum samples of tetanus patients admitted to The Institute for research on Clinical Medicine and Tropical Diseases from November 1996 to May 1997 were analysed by technique of inoculation in mice. The results showed that: 1) Free circulating tetanus toxin was detected in 19% of cases with 5.1% of cases with 5.1% of cases of low toxin concentration and 13.9% of cases of high toxin concentration. All them are negative after 5 days of ATS injection (Anti Tetanus Serum) with 6000-9000 IU (M.I). 2) The presence of free circulating tetanus toxin in the blood was not related to infectious condition of the wound (P>0.05). 3) Mortality in the group with positive free tetanus toxin (60%) are higher significantly (p<0.01) than the negative one (20.3%). So, free circulating tetanus toxin in the blood had a severe prognostic value in tetanus patients. 4) Using ATS was necessary for the treatment of tetanus patients. 5) Serum antitoxin concentration in most of tetanus patients (90%) was lower than the 'protective level' (<0.01IU/ml).
Tetanus ; Bood

79 sera of tetanus patients (Institute for Clinical Research in Tropical Diseases 1966, 1967, 1996 to 1997 were investigated for circulating toxin, using the mouse inoculation technique). Results: free circulating tetanus toxin was detected in 19,0% cases, among them 5,1% had low toxic concentration and 13,9% had high toxic concentration. The presence of free circulating tetanus toxin in the blood was not related to the infectious condition of the wound at admission. The mortality in the group with positive free circulating tetanus toxic was higher 60% than this in the negative one. So the presence of free circulating tetanus toxin in the blood had a prognostic value in tetanus patients. The use of tetanus antitoxin was necessary in the treatment of tetanus patients to neutralize free circulating tetanus toxin.
Tetanus ; Bood

Samples of 22 batches of adsorbed tetanus toxoid, produced at IVAC between 1995 and 2000 were checked for their potency at 24, 36, 42, 48 and 60 months after production. The results showed that: the potency did not change after 42 months of storage at 4oC. From 48 months afterward the potency decreased.
Vaccines ; Tetanus

74 patients with severe tetanus who have indication of artificial ventilation were evaluated. These patients were 15 years old or less at baseline. Participants were divided into 2 groups. Group 1 (40 patients) had received artificial ventilation, and group 2 (34 patients) had not received artificial ventilation due to the ventilators were not available. The mortality of groups 1 was 60% (16/40) and that of group 2 was 94.12% (32/34). Ventilators are very helpful in the management of severe tetanus but their complications caused many problems
Tetanus ; Pediatrics

The decoloration of purified sera was achieved by using 0.1% caprylic acid solution with pH 4.2 at 56oC. The technique can shorten the duration of purification processes
tetanus antitoxin